Abstract:Lung cancer remains one of the leading causes of cancer-related mortality worldwide, necessitating innovative research methodologies to improve treatment outcomes and develop novel strategies. The advent of three-dimensional (3D) cell cultures has marked a significant advancement in lung cancer research, offering a more physiologically relevant model compared to traditional two-dimensional (2D) cultures. This review elucidates the various types of 3D cell culture models currently used in lung cancer pharmacology, including spheroids, organoids and engineered tissue models, having pivotal roles in enhancing our understanding of lung cancer biology, facilitating drug development, and advancing precision medicine. 3D cell culture systems mimic the complex spatial architecture and microenvironment of lung tumours, providing critical insights into the cellular and molecular mechanisms of tumour progression, metastasis and drug responses. Spheroids, derived from commercialized cell lines, effectively model the tumour microenvironment (TME), including the formation of hypoxic and nutrient gradients, crucial for evaluating the penetration and efficacy of anti-cancer therapeutics. Organoids and tumouroids, derived from primary tissues, recapitulate the heterogeneity of lung cancers and are instrumental in personalized medicine approaches, supporting the simulation of in vivo pharmacological responses in a patient-specific context. Moreover, these models have been co-cultured with various cell types and biomimicry extracellular matrix (ECM) components to further recapitulate the heterotypic cell-cell and cell-ECM interactions present within the lung TME. 3D cultures have been significantly contributing to the identification of novel therapeutic targets and the understanding of resistance mechanisms against conventional therapies. Therefore, this review summarizes the latest findings in drug research involving lung cancer 3D models, together with the common laboratory-based assays used to study drug effects. Additionally, the integration of 3D cell cultures into lung cancer drug development workflows and precision medicine is discussed. This integration is pivotal in accelerating the translation of laboratory findings into clinical applications, thereby advancing the landscape of lung cancer treatment. By closely mirroring human lung tumours, these models not only enhance our understanding of the disease but also pave the way for the development of more effective and personalized therapeutic strategies.

Advancing cancer therapeutics: Integrating scalable 3D cancer models, extracellular vesicles, and omics for enhanced therapy efficacy

3D cancer models: One step closer to in vitro human studies

Breaking the mold: 3D cell cultures reshaping the future of cancer research

A comprehensive review of 3D cancer models for drug screening and translational research

Three-Dimensional In Vitro Cell Cultures as a Feasible and Promising Alternative to Two-Dimensional and Animal Models in Cancer Research

Mimicking 3D breast tumor-stromal interactions to screen novel cancer therapeutics

Modelling the complex nature of the tumor microenvironment: 3D tumor spheroids as an evolving tool

3D cell culture models in research: applications to lung cancer pharmacology

The progress and challenges in modeling colorectal cancer and the impact on novel drug discovery

Leveraging and Manufacturing in Vitro Multicellular Spheroid-Based Tumor Cell Model As a Preclinical Tool for Translating Dysregulated Tumor Metabolism into Clinical Targets and Biomarkers

3D Cell Culture Models as Recapitulators of the Tumor Microenvironment for the Screening of Anti-Cancer Drugs

Replacement, Reduction, and Refinement of Animal Experiments in Anticancer Drug Development: The Contribution of 3D In Vitro Cancer Models in the Drug Efficacy Assessment

Abstract 651: 3D-bioprinted cancer models for target discovery, drug development, and personalized therapy

New approaches in extracellular vesicle engineering for improving the efficacy of anti-cancer therapies

Integration of pan-omics technologies and three-dimensional in vitro tumor models: an approach toward drug discovery and precision medicine

Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation

Preclinical Cancer Models and Biomarkers for Drug Development: New Technologies and Emerging Tools

Application of 3D cultured multicellular spheroid tumor models in tumor-targeted drug delivery system research.

3D Tumor Spheroid and Organoid to Model Tumor Microenvironment for Cancer Immunotherapy

Modeling intratumor heterogeneity in breast cancer

Biologically-Relevant 3d Tumor Arrays: Treatment Response and the Importance of Stromal Partners